{"id":366,"date":"2020-02-03T13:23:20","date_gmt":"2020-02-03T12:23:20","guid":{"rendered":"https:\/\/porphyria.network\/IPPN\/?p=366"},"modified":"2021-09-13T10:04:41","modified_gmt":"2021-09-13T08:04:41","slug":"the-ema-recommends-givosiran-for-ahp","status":"publish","type":"post","link":"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/","title":{"rendered":"The EMA recommends givosiran for AHP!"},"content":{"rendered":"\n<p>Following last November&#8217;s <a href=\"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/\">FDA approval<\/a>, the European Medicines Agency (EMA) has recommended givosiran (Givlaari) for market authorization approval to treat people with acute hepatic porphyria in the European Union. Givosiran was reviewed under EMA&#8217;s accelerated assessment programme.<\/p>\n\n\n\n<p> If approved by the&nbsp;European Commission, this will represent yet another important step twoards addressing the needs of individuals affected by painful, recurrent acute hepatic porphyria attacks. Relieving the suffering caused by this debilitating, life-threatening condition is now within reach and the IPPN calls on all stakeholders and decision-makers (drug manufacturer, health technology assessment bodies, heath insurers and, overall, national healthcare systems) to reach the necessary agreements to ensure swift treatment access for patients.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.ema.europa.eu\/en\/news\/first-treatment-acute-hepatic-porphyria\"><strong>EMA Press Release On Givosiran&#8217;s Marketing Authorization Recommendation<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following last November&#8217;s FDA approval, the European Medicines Agency (EMA) has recommended givosiran (Givlaari) for market authorization approval to treat people with acute hepatic porphyria in the European Union. Givosiran was reviewed under EMA&#8217;s accelerated assessment programme. If approved by the&nbsp;European Commission, this will represent yet another important step twoards addressing the needs of individuals&hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[31],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.6.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The EMA recommends givosiran for AHP! - International Porphyria Patient Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The EMA recommends givosiran for AHP! - International Porphyria Patient Network\" \/>\n<meta property=\"og:description\" content=\"Following last November&#8217;s FDA approval, the European Medicines Agency (EMA) has recommended givosiran (Givlaari) for market authorization approval to treat people with acute hepatic porphyria in the European Union. Givosiran was reviewed under EMA&#8217;s accelerated assessment programme. If approved by the&nbsp;European Commission, this will represent yet another important step twoards addressing the needs of individuals&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/\" \/>\n<meta property=\"og:site_name\" content=\"International Porphyria Patient Network\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-03T12:23:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-13T08:04:41+00:00\" \/>\n<meta name=\"author\" content=\"Editorial Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Editorial Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/\"},\"author\":{\"name\":\"Editorial Team\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\"},\"headline\":\"The EMA recommends givosiran for AHP!\",\"datePublished\":\"2020-02-03T12:23:20+00:00\",\"dateModified\":\"2021-09-13T08:04:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/\"},\"wordCount\":126,\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"articleSection\":[\"English\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/\",\"name\":\"The EMA recommends givosiran for AHP! - International Porphyria Patient Network\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\"},\"datePublished\":\"2020-02-03T12:23:20+00:00\",\"dateModified\":\"2021-09-13T08:04:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/porphyria.network\/IPPN\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The EMA recommends givosiran for AHP!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"name\":\"International Porphyria Patient Network\",\"description\":\"Welcome to the International Porphyria Patient Network\",\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\",\"name\":\"International Porphyria Patient Network\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"contentUrl\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"width\":671,\"height\":630,\"caption\":\"International Porphyria Patient Network\"},\"image\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\",\"name\":\"Editorial Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"caption\":\"Editorial Team\"},\"url\":\"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The EMA recommends givosiran for AHP! - International Porphyria Patient Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/","og_locale":"en_US","og_type":"article","og_title":"The EMA recommends givosiran for AHP! - International Porphyria Patient Network","og_description":"Following last November&#8217;s FDA approval, the European Medicines Agency (EMA) has recommended givosiran (Givlaari) for market authorization approval to treat people with acute hepatic porphyria in the European Union. Givosiran was reviewed under EMA&#8217;s accelerated assessment programme. If approved by the&nbsp;European Commission, this will represent yet another important step twoards addressing the needs of individuals&hellip;","og_url":"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/","og_site_name":"International Porphyria Patient Network","article_published_time":"2020-02-03T12:23:20+00:00","article_modified_time":"2021-09-13T08:04:41+00:00","author":"Editorial Team","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Editorial Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/#article","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/"},"author":{"name":"Editorial Team","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765"},"headline":"The EMA recommends givosiran for AHP!","datePublished":"2020-02-03T12:23:20+00:00","dateModified":"2021-09-13T08:04:41+00:00","mainEntityOfPage":{"@id":"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/"},"wordCount":126,"publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"articleSection":["English"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/","url":"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/","name":"The EMA recommends givosiran for AHP! - International Porphyria Patient Network","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/#website"},"datePublished":"2020-02-03T12:23:20+00:00","dateModified":"2021-09-13T08:04:41+00:00","breadcrumb":{"@id":"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/porphyria.network\/IPPN\/2020\/02\/the-ema-recommends-givosiran-for-ahp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/porphyria.network\/IPPN\/"},{"@type":"ListItem","position":2,"name":"The EMA recommends givosiran for AHP!"}]},{"@type":"WebSite","@id":"https:\/\/porphyria.network\/IPPN\/#website","url":"https:\/\/porphyria.network\/IPPN\/","name":"International Porphyria Patient Network","description":"Welcome to the International Porphyria Patient Network","publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/porphyria.network\/IPPN\/#organization","name":"International Porphyria Patient Network","url":"https:\/\/porphyria.network\/IPPN\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/","url":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","contentUrl":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","width":671,"height":630,"caption":"International Porphyria Patient Network"},"image":{"@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765","name":"Editorial Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","caption":"Editorial Team"},"url":"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/"}]}},"_links":{"self":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/366"}],"collection":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/comments?post=366"}],"version-history":[{"count":4,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/366\/revisions"}],"predecessor-version":[{"id":371,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/366\/revisions\/371"}],"wp:attachment":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/media?parent=366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/categories?post=366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/tags?post=366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}